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Abstract.
Background: As tau aggregation pathology correlates with clinical dementia in Alzheimer’s disease (AD), a tau aggregation
inhibitor (TAI) could have therapeutic utility. Methylthioninium (MT) acts as a selective TAI in vitro and reduces tau pathology
in transgenic mouse models.
Objective: To determine the minimum safe and effective dose of MT required to prevent disease progression on clinical and
functional molecular imaging outcomes.
Methods: An exploratory double-blind, randomized, placebo-controlled, dose-finding trial of MT (69, 138, and 228 mg/day)
was conducted in 321 mild/moderate AD subjects. The primary outcome was change on the Alzheimer’s Disease Assessment
Scale-cognitive subscale (ADAS-cog) at 24 weeks relative to baseline severity. Effect of treatment on regional cerebral blood
flow decline was determined in a sub-study in 135 subjects. After 24 weeks, subjects were re-consented to enter sequential
6- and 12-month blinded extension phases. Registered with ClinicalTrials.gov (NCT00515333).
Results: At 24 weeks, there were significant treatment benefits in two independent populations at the 138 mg/day dose: in
moderate subjects on the ADAS-cog scale (treatment effect: −5.42 units, corrected p = 0.047) and two other clinical scales; in
mild subjects on the more sensitive regional cerebral blood flow measure (treatment effect: 1.97%, corrected p < 0.001). With
continued treatment for 50 weeks, benefit was seen on the ADAS-cog scale in both mild and moderate subjects. The delivery of
the highest dose was impaired due to dose-dependent dissolution and absorption limitations.
Conclusion: The minimum safe and effective daily MT dose is 138 mg and suggests that further study of MT is warranted in AD.
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INTRODUCTION
Neurofibrillary tangles discovered by Alois
Alzheimer [1] are made up of paired helical filaments
(PHFs), composed predominantly of a 12 kDa
repeat-domain fragment of the microtubule-associated
protein tau [2–4]. Numerous studies have confirmed
a quantitative link for the spread of neurofibrillary
tangle pathology and the quantity of aggregated
tau with both the extent of clinical dementia and
functional molecular imaging deficits in Alzheimer’s
disease (AD) [5–8]. In light of the repeated failures
of trials targeting the amyloid- pathway in mild or
moderate AD [9], there is increasing interest in the
possibility that a tau aggregation inhibitor (TAI) could
have therapeutic utility in AD [9–11].
Methylthioninium (MT) is a diaminophenothiazine
and, as the chloride salt of oxidized MT+ (MTC,
methylthioninium chloride, “methylene blue”), has
a long history of safe use, both as an approved
treatment for methemoglobinemia [12], and experi-
mentally in urolithiasis and bipolar disorder among
others [13–15]. MT inhibits tau aggregation in vitro
and dissolves PHFs from AD brain tissue [16]. We
have recently reported that the estimated steady state
trough brain concentration of MT and its pharmaco-
logically active desmethyl metabolites in the human
brain at the 138 mg/day dose is 0.18M [17]. This
is in the same range as the IC50 value for dissolution
of PHFs (0.16M) and the calculated intracellular Ki
for TAI activity (0.12M) (Harrington et al., unpub-
lished results). We have also reported elsewhere that
MT produces a monotonic ascending dose-response
in the brain concentration range 0.13–1.38M in tau
transgenic mouse models (Melis et al., Behav. Phar-
macol., in press).
We report the results of the first phase 2 clinical
trial of a TAI in 321 subjects with mild/moderate AD.
The trial was designed as an exploratory double-blind,
randomized, placebo-controlled, 24 week dose-finding
study of MT as monotherapy in AD (Fig. 1). Treat-
ment could be extended in a blinded fashion in two
sequential extension phases. In addition, a nested hexa-
methyl-propyl-amine-oxime single photon emission
computed tomography (HMPAO-SPECT) sub-study
was conducted in 135 of the participating subjects to
explore whether treatment could prevent progression
of molecular imaging deficits. This paper reports the
primary and secondary outcomes at 24 weeks and a
post hoc exploratory analysis at 50 weeks after the
first extension of treatment. Although safety data are
reported from the second extension phase, there were
too few subjects remaining on treatment through to 102
weeks to permit meaningful comparison of treatment
groups.
METHODS
Subjects
English-speaking subjects were enrolled at 17 cen-
ters (UK, 16; Singapore, 1) between 21 September
2004 and 21 December 2007. Subjects had a diagnosis
of probable AD by DSM-IV and NINCDS-ADRDA
criteria, a Mini-Mental State Examination (MMSE)
score between 10 and 26 inclusive and a Clinical
Dementia Rating (CDR) score of 1 or 2 at entry. To
be included and retained in the trial, subjects were not
to be currently treated with cholinesterase inhibitors
or memantine. The full inclusion and exclusion crite-
ria are provided in Supplementary Material S1 and S2,
including competency requirements for consent to par-
ticipate. Apolipoprotein E4 status was not determined
as earlier work had shown that it does not impact on
levels of aggregated tau in the AD brain [18].
Trial design
Subjects were randomized at baseline to placebo
or one of three doses of MT (69 mg, 138 mg, and
228 mg/day, administered as 30 mg, 60 mg, and 100 mg
MTC capsules taken three times per day with food)
using blocks of size 10 (two per dose level). A sep-
arate randomization schedule was used for sites able
to undertake HMPAO-SPECT scans (limiting random-
ization after 31 January 2005 to placebo, 138 mg/day,
or 228 mg/day). The dose range was based on a theoret-
ical pharmacokinetic model developed from published
human and rat data [19, 20], and recommended dos-
ing [21]. Following completion of 24 weeks, subjects
were re-consented to enter sequential 6-month and
12-month extension phases (“E1” and “E2”) with dos-
ing changes indicated in Fig. 1. Dosing frequency
remained the same throughout. In order to main-
tain blinding to the subject and raters, capsules and
treatment packs were identical. Each MTC dose or
placebo was a single dark-blue hard gelatin capsule
and safety raters were not permitted to be efficacy
raters. Alzheimer’s Disease Cooperative Study Clin-
ical Global Impression of Change (ADCS-CGIC) was
independently assessed by a third rater blinded to the
findings of the other two raters. The study remained
double-blind throughout 2 years.
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Fig. 1. Trial design.
The study was conducted in accordance with the
Declaration of Helsinki and in compliance with the
NHS Research Governance Framework, the Interna-
tional Conference on Harmonisation (ICH) Guidelines
for Good Clinical Practice (GCP; CPMP/ICH/135/95,
July 1996), and the European Directive on Clinical
Trials (2004). The trial is registered at http://www.
clinicaltrials.gov (NCT00515333).
Clinical and imaging assessments
The primary efficacy outcome was change in
Alzheimer’s Disease Assessment Scale-cognitive sub-
scale (ADAS-cog) from baseline at 24 weeks.
Secondary efficacy outcomes included ADCS-CGIC
and change in MMSE score. Other secondary rating
instruments and their assessment times are listed in
Supplementary Material S3.
Change in regional cerebral blood flow (rCBF) was
assessed by HMPAO-SPECT scan (see Supplementary
Material S4) in all subjects enrolled at nine partici-
pating UK study sites with this capability. Baseline
SPECT scans (or scans available within the previous
3 months) were performed before randomization. A
follow-up scan was performed at the end of the ini-
tial 24 week study between 18 and 30 weeks after
the first scan. The images were assessed by an expert
neuroradiologist (ADM) and classified according to
presence or absence of temporoparietal lobe reduction
in rCBF.
Subjects were monitored throughout for adverse
events (AEs) and clinical laboratory testing was under-
taken after 6, 12, and 24 weeks. Monitoring and labo-
ratory testing continued during the extension phases.
Statistical methods
The statistical analysis plan was finalized 5 February
2007, and final data lock was on 20 February 2008.
Since the study anticipated the theoretical possibil-
ity of non-response in moderate subjects due to more
advanced pathology in medial temporal lobes [22],
the statistical analysis plan specified that the primary
analysis would assess the interaction between treat-
ment and baseline severity as defined by baseline
CDR (mild or moderate). The primary efficacy anal-
ysis of ADAS-cog change at 24 weeks was modelled
as pre-specified using analysis of covariance, includ-
ing covariates for treatment, baseline severity and a
term for the interaction between treatment and sever-
ity. Additional terms for study center category (four
levels), baseline ADAS-Cog score, age, gender, and
previous exposure to acetylcholinesterase inhibitors
or memantine were included. In the absence of prior
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dose-response information, Westfall’s method, which
does not require an a priori dose-response assumption,
was pre-specified to correct for multiple comparisons
[23]. This was applied separately for subjects with
mild and moderate disease, and the resultant p val-
ues were then further adjusted using the Bonferroni
procedure (multiplied by 2), to provide correction for
6 treatment/severity levels, referred to in tables as
“adjusted”. The analysis was conducted using the mod-
ified intent-to-treat (mITT) population (ITT population
who had at least one post-baseline, on-treatment effi-
cacy assessment) with “last on-treatment observation
carried forward” imputation for withdrawn subjects.
The clinical secondary outcome measures at 24
weeks were analyzed in the same way. ADCS-CGIC
score was analyzed both as a dichotomous variable
(declined versus same/improved) and also as a con-
tinuous variable. Analysis of MMSE was the same as
for ADAS-cog. Mean change from baseline rCBF on
HMPAO-SPECT was analyzed using region of interest
(ROI) and statistical parametric mapping approaches
[24]. For the ROI analysis, rCBF averaged across all
brain regions was analyzed using linear modelling,
with MT dose, a term for the interaction between treat-
ment and severity, and temporoparietal lobe reduction
pattern as fixed factors, and age and interval between
scans as covariates. In addition, a statistical paramet-
ric mapping (SPM) approach was used to define the
regions in which treatment response was seen without
a priori brain mapping assumptions.
An exploratory analysis of ADAS-cog at 50 weeks
was conducted using the same primary analysis model
as for 24 weeks. Subjects randomized to placebo and
then receiving a nominal dose of 152 mg/day during
weeks 24–50 served as the control arm for assessment
of treatment effect at 50 weeks.
Analysis of available dose
The experimental procedures and results of
stability/dissolution studies of the capsules used in
the trial undertaken at the time the trial was initi-
ated are reported in Baddeley et al. [17]. Likewise,
the procedures and results of single-dose fed/fasting
studies of MTC and a novel stable reduced form of
MT (LMTX®), and a repeated-dose study of MTC, are
reported in Baddeley et al. [17]. The calculation of total
available dose and dose according to release within
or after 60 min and the corresponding dose-response
analyses of ADAS-cog effect size at 24 weeks and
effect on reduction in red cell count have been reported
previously [17].
Role of the funding source
The study was financed entirely by TauRx
Therapeutics Ltd. TauRx took the lead in study design
and study conduct.
RESULTS
Subjects
Subject disposition is summarized in Fig. 1. Of 321
subjects randomized, 294 were in the mITT popu-
lation; of these 238, 176, and 62 (81%, 60%, and
21%) remained on treatment at 24, 50, and 102 weeks,
respectively. Baseline demographics and clinical char-
acteristics are provided in Table 1. Overall, subjects
were balanced with respect to severity of baseline dis-
ease based on MMSE. Of the 238 participants who
completed the 24 week study, 135 (57%) were imaged
twice (after a mean of 20.3 weeks of treatment) and
had images suitable for analysis.
Primary analysis of ADAS-cog outcome at 24
weeks
Table 2 reports change in ADAS-cog score and
difference with respect to placebo by treatment arm
and baseline CDR-severity. The changes in ADAS-cog
from baseline to 24 weeks in all subjects are plot-
ted in Fig. 2A. The lower dose of 69 mg/day did not
differ statistically from placebo. Dose-dependent for-
mulation and absorption factors affecting the highest
strength capsules [17] confound interpretation of the
228 mg/day nominal dose group on this and all other
outcome measures and are discussed further below.
In the absence of placebo decline in subjects with
mild disease over 24 weeks, no treatment benefit with
MT could be observed. Subjects with moderate dis-
ease declined by an average of 4.3 ADAS-cog units
over 24 weeks. The 138 mg MT/day dose was effec-
tive in preventing clinical decline and the treatment
effect was statistically significant (Table 2; p = 0.008,
corrected p = 0.047). Therefore, the conclusion of the
pre-specified primary efficacy analysis in the mITT
population is that treatment at 138 mg/day is effective.
Analyses of secondary clinical outcomes at 24
weeks
TheplotsofchangeinADCS-CGICandMMSEfrom
baseline to24weeksareprovided inFig.2BandC.Both
analyses showed a statistically significant treatment
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Table 1
Subject baseline demographics and clinical characteristics
Characteristic Placebo 69 mg/day 138 mg/day 228 mg/day Total
(n = 92) (n = 59) (n = 80) (n = 90) (n = 321)
Age (years):
Mean (SD) 74.6 (8.1) 73.4 (8.7) 73.8 (9.9) 73.3 (9.4) 73.8 (9.0)
Gender:
Male, n (%) 47 (51%) 26 (44%) 33 (41%) 43 (48%) 149 (46%)
Female, n (%) 45 (49%) 33 (56%) 47 (59%) 47 (52%) 172 (54%)
Race:
Afro-Caribbean, n (%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 1 (0%)
Asian, n (%) 8 (9%) 1 (2%) 8 (10%) 6 (7%) 23 (7%)
Caucasian, n (%) 83 (90%) 58 (98%) 72 (90%) 84 (93%) 297 (93%)
Years since diagnosis:
Mean (SD) 0.86 (1.18) 1.00 (1.47) 0.89 (1.46) 0.85 (1.11) 0.89 (1.29)
Dementia severity:
CDR mild, n (%) 72 (78%) 41 (69%) 63 (79%) 76 (84%) 252 (79%)
CDR moderate, n (%) 20 (22%) 18 (31%) 17 (21%) 14 (16%) 69 (21%)
MMSE:
Mean (SD) 19.6 (4.6) 18.5 (4.7) 19.7 (4.6) 19.4 (4.6) 19.4 (4.6)
MMSE severity:
MMSE<20, n (%) 44 (47.8) 28 (47.5) 36 (45.1) 42 (46.7) 150 (46.7)
MMSE ≥ 20, n (%) 48 (52.2) 31 (52.5) 44 (54.9) 48 (53.3) 171 (53.3)
ADAS-Cog:
Mean (SD) 24.5 (10.4) 26.9 (10.5) 23.3 (8.9) 24.7 (11.0) 24.6 (10.3)
ADAS-Cog, Alzheimer’s Disease Assessment Scale – Cognitive subscale; CDR, Clinical Dementia Rating; MMSE, Mini-Mental State Exam-
ination; SD, standard deviation.
Table 2
Change from baseline in ADAS-Cog score and MT treatment effect for subjects with mild and moderate disease severity at 24 weeks
Change from baseline Treatment effect
Estimate (95% CI) p Estimate (95% CI) p p-adj
MILD
Placebo −0.14 (−1.40, 1.11) 0.826
69 mg/day 0.91 (−0.82, 2.63) 0.301 1.05 (−1.08, 3.17) 0·333 1
138 mg/day −0.32 (−1.74, 1.10) 0.654 −0.18 (−2.06,1.69) 0.846 1
228 mg/day −0.87 (−2.15, 0.40) 0.347 −0.73 (−2.51, 1.05) 0.419 1
MODERATE
Placebo 4.35 (1.78, 6.91) 0.001
69 mg/day 1.35 (−1.32, 4.01) 0.32 −3.00 (−6.47, 0.47) 0.09 0.325
138 mg/day −1.08 (−4.36, 2.21) 0.52 −5.42 (−9.44, −1.41) 0.008 0.047
228 mg/day 3.95 (−0.64, 7.26) 0.019 −0.39 (−4.28, 3.50) 0.843 1
The column labelled “p-adj” provides the adjusted p-values after Westfall/Bonferroni correction for multiple comparisons with 6
dose/severity levels. Also shown are the change from baseline in each of the four study arms at each of two levels of baseline CDR-severity,
and the p-value for testing if the change from baseline differs significantly from zero. CI, confidence interval.
effect at the 138 mg/day dose in moderate subjects. For
the continuous analysis of ADCS-CGIC, the effect size
was 1.29 units (95% CI = [0.43, 2.16]; p = 0.0036; cor-
rected p = 0.021); in the categorical analysis, the effect
size was 2.17 log-odds units (95% CI = [0.40, 4.32];
p = 0.025; corrected p = 0.14; odds-ratio=8.8). Similar
results were found for change in MMSE score from
baseline.Theeffect sizewas3.79units (95%CI = [1.16,
6.41]; p = 0.0048; corrected p = 0.028). No other sec-
ondary clinical outcome measures were significant. No
change from baseline was observed on any scale in mild
subjects receiving placebo.
Imaging outcomes at 24 weeks
Change in rCBF over approximately 24 weeks was
analyzed as a secondary outcome in a subset of 135
subjects randomized to sites with SPECT imaging
capability. Plots of change in mean rCBF for mild
and moderate subjects are provided in Fig. 2D. The
analysis of mean change in rCBF averaged across all
ROIs is provided in Table 3. SPECT imaging was suf-
ficiently sensitive to show significant placebo decline
in mild subjects. There was significantly less decline
in rCBF following treatment with MT 138 mg and
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Fig. 2. Clinical and imaging outcomes at 24 weeks for mild and moderate AD.
228 mg/day nominal doses (corrected p < 0.001 and
0.031, respectively). The effect size at 138 mg/day was
91% of the decline in the corresponding placebo group.
In moderate subjects, known to have more advanced
perfusion deficits [25], the further placebo decline was
non-significant and there was no evidence of treatment
benefit.
In the analysis of rCBF change in individual
ROIs (Fig. 3A), mild subjects receiving placebo had
significant rCBF decline in all regions. At the
138 mg/day dose, all regions other than the left frontal
lobe were significantly different from placebo at
the p < 0.05 level. In the SPM analysis, the regions
with statistically significant differences relative to
placebo in subjects receiving any does of MT are
illustrated in Fig. 3B, the differences being greatest
bilaterally in the medial temporal and temporoparietal
regions.
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Table 3
Percentage change from baseline in relative cerebral blood flow (rCBF, normalized to cerebellum) and MTC treatment effect for subjects with
mild and moderate disease severity after mean 20 weeks of treatment
Change from baseline Treatment effect
Estimate (95% CI) p Estimate (95% CI) p p-adj
MILD
Placebo −2.16 (−2.72, −1.61) <0.001
69 mg/day −1.48 (−2.57, −0.39) 0.008 0.62 (−0.54, 1.91) 0.275 0.697
138 mg/day −0.19 (−0.96, 0.57) 0.621 1.97 (1.02, 2.92) <0.001 <0.001
228 mg/day −0.96 (−1.62, 0.30) 0.004 1.12 (0.34, 2.06) 0.006 0.031
MODERATE
Placebo −0.92 (−2.14, 0.30) 0.138
69 mg/day −1.30 (−3.12, 0.52) 0.16 −0.38 (−2.59,1.82) 0.733 0.923
138 mg/day −1.53 (−3.01, −0.05) 0.043 −0.61 (−2.51,1.29) 0.529 0.877
228 mg/day −0.012 (−2.62, 0.14) 0.079 −0.32 (−2.17, 0.15) 0.737 0.923
p-adj, adjusted p-value after Westfall/Bonferroni correction for multiple comparisons with 6 dose/severity levels. CI, confidence interval.
Exploratory post hoc analysis of ADAS-cog
change during ﬁrst extension phase
With continued treatment for up to 50 weeks, decline
was evident in subjects who entered the study with mild
disease and were randomized to placebo (and then con-
verted after 24 weeks to capsules with dose-dependent
delivery limitations [17]). Patients randomized to MT
138 mg/day, whether mild or moderate at baseline,
did not decline and there was a statistically signifi-
cant treatment benefit of 2.8 to 5.2 ADAS-cog units in
mild and moderate subjects, respectively (see Table 4).
These effect sizes represent 96% and 91%, respec-
tively, of the decline seen in the corresponding control
arms.
The ADAS-cog effect sizes in mild subjects at 50
weeks reported in Table 4 were compared with imaging
effect sizes observed in mild subjects at approximately
24 weeks reported in Table 3. As can be seen from
Fig. 4, the 138 mg/day dose was the most effective dose
in both modalities. The mean treatment benefit seen
by SPECT scan at approximately 24 weeks in mild
subjects was highly correlated with the mean clinical
effect size measured on the ADAS-cog scale in mild
subjects at 50 weeks (r = 0.989).
Safety
Table 5 provides an overview of treatment emergent
AEs, during the placebo-controlled and E1/E2 peri-
ods, most of which were considered moderate or mild.
The most commonly reported AEs (incidence ≥ 5%)
in MTC-treated subjects included gastrointestinal dis-
orders (primarily diarrhea), renal and urinary disorders
(primarily dysuria and frequency), and falls (Table 6
and Supplementary Material S5). A larger proportion
of subjects randomized to MTC experienced at least
one AE leading to interruption of study drug or perma-
nent discontinuation compared with those randomized
to placebo by 24 weeks. The overall incidence of AEs
and AEs requiring a change in dosing was greatest at
the 138 mg/day dose.
Eight deaths were reported while participating in the
study or shortly after discontinuing. Of the six deaths
which occurred in MTC-treated subjects, one was from
cancer and five were of a cardiovascular or hemor-
rhagic etiology in subjects with known risk factors;
none were attributed to MTC.
No changes of clinical significance were observed
in any routine clinical chemistry parameters in any
treatment group. Treatment with MTC produced dose-
dependent decreases in red cell count and hemoglobin
and increases in methemoglobin (Fig. 5; Supple-
mentary Material S6). There were 4 cases (of 307
exposed to MTC) with methemoglobin greater than
3.5% (a threshold set for withdrawal of treatment)
which resolved on cessation of treatment. There were
no cases of clinically significant anemia. Initial dose-
dependent decreases in white-blood cell counts were
also observed which did not progress beyond 24 weeks
(Supplementary Material S7).
Post-hoc dose-response analyses
The response profiles with respect to nominal dose
for the ADAS-cog effect at 24 weeks (Fig. 6A),
the SPECT scan effect at approximately 24 weeks
(Fig. 6B), the ADAS-cog effect at 50 weeks (Fig. 6 C),
and the percentage of subjects with at least one AE
leading to discontinuation or dose interruption at 24
weeks (Fig. 6D) show that the effects at the 228 mg/day
nominal dose were consistently less than those at the
138 mg/day dose on all outcomes.
712 C.M. Wischik et al. / Phase 2 AD Trial of Tau Aggregation Inhibitor
A
B
Fig. 3. Percentage change in rCBF SPECT adjusted mean values (normalized to the cerebellum) between baseline and follow-up in mild subjects.
A) Differences with respect to placebo were significant at p < 0.05 for the 69 mg/day dose only in the right temporal lobe, for the 138 mg/day
dose in all lobes except the left frontal lobe, and for the 228 mg/day dose in right and left temporal lobes and in left occipital lobe. B) Results
of statistical parametric mapping comparison of change in blood flow between those receiving MTC versus placebo in mild AD subjects. The
significant differences are in areas of the brain typically involved with neurofibrillary tangle pathology, i.e., treatment with MT has resulted in
significantly less blood flow decline (or in some preservation of blood flow) in colored regions.
The100 mgMTCgelatincapsuleformulationusedto
deliver the 152 mg and 228 mg MT/day nominal doses
wasknown,atthetimethatthestudywasinitiated,tosuf-
ferfromadose-dependentdissolutionlimitationinwater
and simulated gastric fluid, although not in simulated
intestinal fluid. In addition, a subsequent fed/fasting
study showed that there was a dose-dependent limita-
tion in the absorption of MT given as MTC with food,
affectingparticularlythe100 mgMTCunitdosethatwas
independent of the formulation defect. Taking account
of both of these factors, the calculated total dose of MT
available forabsorption is showninFig.7A,comprising
MT released within 60 min in water or simulated gastric
fluid,orafter60 minandreleased insimulated intestinal
fluid.Thetotalavailabledoseishighlycorrelatedwiththe
SPECT scan effect size at 24 weeks (Fig. 7B, r = 0.974),
theADAS-cogeffectsizeat50weeks(Fig.7 C,r = 0.983)
and the percentage of subjects with at least one AE lead-
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Table 4
Change from baseline in ADAS-Cog score and MT treatment effect for subjects with mild and moderate disease severity at 50 weeks
Change from baseline Treatment effect
Estimate (95% CI) p Estimate (95% CI) p
MILD
Placebo 152 mg/day 2.94 (1.53, 4.35) <0.001
69 mg/day 3.06 (1.11, 5.01) 0.002 0.12 (−2.28, 2.52) 0.921
138 mg/day 0.13 (−1.48, 1.73) 0.877 −2.81 (−4.93, −0.70) 0.009
228 mg/day 1.50 (0.06, 2.94) 0.041 −1.44 (−3.45, 0.57) 0.16
MODERATE
Placebo 152 mg/day 5.51 (2.61, 8.40) 0.002
69 mg/day 4.16 (1.15, 7.17) 0.007 −1.35 (−5.27, 2.57) 0.498
138 mg/day 0.32 (−3.39, 4.04) 0.864 −5.18 (−9.72, −0.65) 0.025
228 mg/day 4.08 (0.35, 7.82) 0.032 −1.42 (−5.81, 2.97) 0.524
CI, confidence interval.
Fig. 4. Comparison of ADAS-cog effect size in mild AD at 50 weeks with the imaging effect sizes at approximately 24 weeks in mild AD.
Table 5
Summary of treatment-emergent adverse events (AEs)
24 week study E1 E2
Placebo 69 mg 138 mg 228 mg All MT All MT
n = 92 n = 59 n = 80 n = 90 n = 227 n = 170
Total number of AEs 161 142 198 248 322 289
At least one AE, n (%) 61 (66.3) 43 (72.9) 67 (83.7) 70 (77.8) 139 (61.2) 96 (56.5)
At least one AE related to study
drug, n (%)
22 (23.9) 30 (50.8) 48 (60.0) 53 (58.9) 65 (28.6) 36 (21.2)
At least one severe AE, n (%) 4 (4.3) 2 (3.4) 8 (10.0) 8 (8.9) 10 (4.4) 14 (8.2)
At least one AE leading to
discontinuation/interruption
of study drug, n (%)
7 (7.6) 12 (20.3) 34 (42.5) 26 (28.9) 36 (15.9) 23 (13.5)
AEs resulting in permanent
discontinuation, n (%)
4 (4.3) 6 (10.2) 28 (35.0) 21 (23.3) 20 (8.8) 16 (9.4)
Treatment emergent severe
AE, n (%)
12 (13.0) 2 (3.4) 13 (16.3) 11 (12.2) 21 (9.3) 26 (15.3)
ing to discontinuation or dose interruption at 24 weeks
(Fig.7D,r = 0.976).ThecorrelationbetweenADAS-cog
effect at 24 weeks and total available dose was weaker
(r = 0.664), but was better correlated with dose avail-
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Table 6
Number (%) of subjects with at least one treatment-emergent adverse event (AE) with an incidence of ≥5% of subjects in any treatment group
(placebo-controlled safety population)
All MT MT Exposed
(n = 307) ≥ 365 days
All AE Treatment-related AE (n = 151)
Number of subjects with at least one AE 268 (87.3%) 184 (59.9%) 80 (52.9%)
Gastrointestinal disorders:
Constipation 15 (4.9%) 4 (1.3%) 1 (0.7%)
Diarrhea 89 (29.0%) 79 (25.7%) 7 (4.6%)
Dyspepsia 14 (4.6%) 9 (2.9%) 1 (0.7%)
Nausea 20 (6.5%) 14 (4.6%) 4 (2.6%)
Vomiting 19 (6.2%) 14 (4.6%) 2 (1.3%)
Peripheral edema 14 (4.6%) 3 (1.0%) 2 (1.3%)
Infections and infestations:
Lower respiratory tract infection 27 (8.8%) 1 (0.3%) 6 (4.0%)
Urinary tract infection 27 (8.8%) 3 (1.0%) 9 (6.0%)
Fall 29 (9.4%) 6 (2.0%) 5 (3.3%)
Dizziness 22 (7.2%) 8 (2.6%) 4 (2.6%)
Depression 13 (4.2%) 3 (1.0%) 2 (1.3%)
Renal and urinary disorders:
Dysuria 21 (6.8%) 20 (6.5%) 1 (0.7%)
Micturition urgency 20 (6.5%) 20 (6.5%) 1 (0.7%)
Pollakiuria 40 (13.0%) 39 (12.7%) 3 (1.0%)
Urinary incontinence 18 (5.9%) 15 (4.9%) 1 (0.7%)
Rash 16 (5.2%) 6 (2.0%) 5 (3.3%)
Fig. 5. Change in red blood cell count from baseline to 24 weeks by
dose.
able for absorption within 60 min (Fig. 8A, r = 0.835).
Reductioninredbloodcellcountat24weekswashighly
correlatedwithdoseavailableforabsorptionafter60 min
(Fig. 8B, r = 0.955).
DISCUSSION
The primary aim of this study was to determine
whether treatment with a TAI has potential utility in the
treatment of AD and, if so, to determine the minimum
safe and effective dose and likely treatment effect
size for further investigation. The primary efficacy
analysis at 24 weeks showed that treatment with MT
138 mg/day is the minimum effective dose required to
prevent disease progression in subjects with baseline
disease of moderate severity. Efficacy was confirmed
in an independent population using more sensitive
imaging measures in subjects with baseline mild dis-
ease. Specifically, in the pre-specified primary efficacy
analysis model, treatment with 138 mg/day produced
statistically significant benefit with respect to placebo
on the ADAS-cog scale (corrected p = 0.047) at 24
weeks in patients with moderate AD at baseline,
even after correcting conservatively for multiple
comparisons. Significant effects were also seen on
the ADCS-CGIC and MMSE secondary outcome
scales. A significant treatment effect was seen at the
same dose on the overall rCBF imaging outcome in a
separate population (mild subjects) at approximately
24 weeks after applying similar corrections. Similar
conclusions are drawn if one uses a linear mixed
effects analysis with an unstructured correlation
matrix without imputation. In these analyses, used
in current phase 3 clinical trials, the treatment effect
at the 138 mg/day dose was significant in moderate
subjects at 24 weeks (p = 0.023) and in the combined
mild/moderate population at 50 weeks (p = 0.0073).
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Fig. 6. There is no dose-response relationship for the 228 mg/day or the 152 mg/day doses of MT delivered via 100 mg MTC capsules for
cognitive effects, SPECT rCBF effects or frequency of adverse events. A) ADAS-cog effect size at 24 weeks in moderate subjects versus
nominal dose. B) SPECT rCBF effect size at 24 weeks in mild subjects versus nominal dose. C) ADAS-cog effect size at 50 weeks in all subjects
versus nominal dose. D) Percentage of subjects with adverse events resulting in dose interruption or discontinuation versus nominal dose.
None of the clinical, imaging, or overall safety
effects increased monotonically with respect to the
nominal dose. In the absence of any prior knowledge of
dose-effect, the Westfall correction for multiple com-
parisons was specified a priori because it does not
assume monotonic dose-response and permits inde-
pendent statements to be made about effectiveness at
any dose/severity level compared to 5% for a test with
family-wise type 1 error probability of 5%.
The failure of the 228 mg/day nominal dose of MT
was entirely unexpected, and has taken a consider-
able body of work to understand (reported in [17]).
In summary, MT is a redox molecule and, depending
on environmental conditions (e.g., pH, oxygen, reduc-
ing agents), exists in equilibrium between a reduced
(leuco-methylthioninium, LMT) and oxidized form
(MT+). As the chloride salt (MTC) used in the phase
2 trial, MT exists entirely in the MT+ form in an oxy-
gen atmosphere. Active conversion to the LMT form
is required to permit absorption by passive diffusion
[17, 26]. This conversion occurs optimally in the stom-
ach, likely due to the pH dependence of the MT redox
potential [27]. MTC is therefore a pro-drug, and the
absorption and disposition of MT depend both on the
fed/fasting status and on dissolution time of the formu-
lation administered [17].
716 C.M. Wischik et al. / Phase 2 AD Trial of Tau Aggregation Inhibitor
Fig. 7. There are simple dose-response relationships for calculated total dose which can be absorbed in the presence of food. A) Total available
dose and dose available for absorption within 60 min or after 60 min. B) SPECT rCBF effect size at 24 weeks in mild subjects versus total
available dose (r = 0.974). C) ADAS-cog effect size at 50 weeks in all subjects versus total available dose (r = 0.983). D) Percentage of subjects
with at least one adverse event resulting in dose interruption or discontinuation versus total available dose (r = 0.976). [(A) is reproduced, with
permission, from Baddeley et al. [17]].
MTC is poorly tolerated in the absence of food and
is subject to dose-dependent absorption interference
when administered with food. This effect proved to be
the predominant determinant of dose-response for the
SPECT scan effect at 24 weeks, the ADAS-cog effect
at 50 weeks, and the frequency of AEs leading to dose
interruption/discontinuation. The dose-response rela-
tionships with respect to available dose are monotonic
and linear with correlation coefficients for mean effects
all greater than 0.97. Dissolution time within or after
60 min is a further contributory factor accounting for
the ADAS-cog effect at 24 weeks (r = 0.835) and the
hematological effect of MT (r = 0.955). This suggests
a partial dissociation between cognitive and hemato-
logical effects that depends on where in the gut MT is
available for release, presumably reflecting differen-
tial redox processing. It should be noted that there are
also strong correlations between the dose available for
absorption within 60 min and the SPECT scan effect at
24 weeks (r = 0.947), the ADAS-cog effect at 50 weeks
(r = 0.927), and the frequency of AEs leading to dose
interruption/discontinuation (r = 0.953). Of the nomi-
nal dose of 228 mg/day, only 109 mg/day was available
for absorption with food. Therefore, the most effective
dose of 138 mg/day simply represents the highest avail-
able dose tested in this study. In summary, the clinical,
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Fig. 8. Partial dissociation of cognitive and hematological effects at 24 weeks depends on dissolution time in vitro. A) ADAS-cog effect size
at 24 weeks versus dose available for absorption within 60 min (r = 0.835). B) Decline in RBC count (x1012 / L) from baseline versus dose
available for absorption after 60 min (r = 0.955).
imaging, and safety effects of MT are highly deter-
mined by a combination of redox processing in the gut
and ability to absorb MT in the presence of food when
given in the oxidized MT+ form as MTC.
The complex factors affecting absorption and dis-
position of MT redox forms were entirely unknown
at the time the study was designed, or for the last
100 years that MTC has been in clinical use. How-
ever, the unexpected dose-dependent limitations in
the absorption of the 100 mg MTC capsule made the
blinded extension phase of the study to 52 weeks more
informative than would otherwise have been the case.
During weeks 24–50, subjects originally randomized
to placebo received a nominal dose of 152 mg MT/day
administered as 100 mg MTC capsules given twice
daily and an additional placebo capsule to maintain
the blind. The intention was to obtain preliminary
information regarding twice daily dosing using the
highest dose capsules. Since these were particularly
affected by absorption and dissolution limitations, only
73 mg/day of the 152 mg/day nominal dose adminis-
tered during weeks 24–50 was available for absorption
with food. Therefore, subjects originally randomized
to placebo during the first 24 weeks and progressing
to the 152 mg/day nominal dose during weeks 24–50
provided a relatively inactive control arm through to 50
weeks which permitted informative post-hoc compar-
isons to be made with respect to subjects randomized
to active doses who continued with their original ran-
domized doses for 50 weeks.
The placebo decline not seen in mild subjects at 24
weeks was 2.9 ADAS-cog units at 50 weeks in the
control arm, comparable to the mean placebo decline
(3.5 ± 1.8 units [mean ± S.E.]) seen in a meta-analysis
of studies in mild AD subjects at 12 months [28–35]
performed by two of the authors (CMW, DJW). By
contrast, the mean decline seen in mild subjects receiv-
ing the 138 mg/day dose was close to zero, implying
an effect size equivalent to 96% of the decline seen in
the control arm and statistically significant (p = 0.009).
Similarly, the effect size at this dose in moderate sub-
jects was 94% of the decline seen in the control arm
at 50 weeks (p = 0.025). This indicates that notwith-
standing the differences in decline relative to severity
seen in the control arm, the corresponding treatment
effect sizes appear to represent a constant fraction of
decline in the control arm, as would be expected for a
disease-modifying treatment.
It is intriguing that the mean effect size seen by
SPECT scan in the absence of apparent clinical bene-
fit at 24 weeks in mild subjects was highly correlated
with the mean clinical effect in mild subjects seen
on the ADAS-cog scale at 50 weeks (r = 0.989). This
suggests that the benefit seen early in the more sen-
sitive functional molecular imaging modality could
have potential utility as an early predictor of later
clinical benefit. Although FDG-PET is more widely
used for functional molecular imaging of the brain
in the US, both HMPAO-SPECT and FDG-PET are
non-specific tracers that show uptake proportionate to
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cerebral blood flow and glucose uptake, respectively.
As such, they are both indirect measures of normal
brain metabolism. Their contribution to an imaging
diagnosis in AD is the pattern of reduction in blood
flow or glucose uptake in areas of the brain typically
affected by tau aggregation pathology [36]. While both
provide indirect measures of normal brain metabolic
activity (i.e., oxygen and glucose consumption respec-
tively), their ability to demonstrate deficits due to
neuropathology is similar [36, 37]. The spatial resolu-
tion of PET is higher, but by using voxel-based image
analysis methods (as was the case in the present study),
both have comparable accuracy [38].
Deficits shown by HMPAO-SPECT in brain regions
affected by tau aggregation pathology have been shown
to correlate with tau aggregation pathology as mea-
sured by Braak stage [36]. The ROI and SPM analyses
of rCBF decline provide a mapping of the regions of
treatment benefit to those known to be particularly
rich in tangles, notably medial temporal lobe struc-
tures and temporoparietal regions [39]. This supports
the possibility that the clinical and imaging benefits of
MT treatment at 138 mg/day may be due to MT activ-
ity as a TAI. Activity as a TAI is consistent with the
estimated steady state trough brain concentration of
MT at the 138 mg/day dose (0.18M) [17], the IC50
value for dissolution of PHFs (0.16M), the calculated
intracellular Ki for TAI activity (0.12M) (Harrington
et al., unpublished results), and the brain concentra-
tion range over which MT reverses tau pathology and
behavioral deficits in two tau transgenic mouse mod-
els (Melis et al., Behav. Pharmacol., in press). We have
recently reviewed alternative mechanisms of action of
MT that have been proposed in the literature [9]. Most
of these, however, are inconsistent with the concen-
trations of MT that could plausibly be achieved in the
brain following oral dosing in humans.
A secondary aim of the study was to explore the
safety and tolerability of MT in AD. The safety pro-
file observed in this study is in keeping with previous
reports of oral MTC use [13–15, 21]. Gastrointesti-
nal and urological effects are the most common; these
were also the most common reason for discontinua-
tion. MTC is known to be associated with dose-related
anemia. Effects seen in this study generally were not
clinically significant.
There are other important limitations to this study
in addition to the formulation and absorption limita-
tions of the highest dose capsules. Although large by
phase 2 standards, this exploratory study was designed
as dose-finding, with the result that the number of sub-
jects was small in the treatment arm of greatest interest
in retrospect. The treatment benefit at 138 mg/day was
seen in only 17 moderate subjects in the analysis of
ADAS-cog at 24 weeks and in 25 mild subjects by
HMPAO-SPECT, although there were 68 subjects in
the post-hoc 50-week analysis. Nevertheless, the pre-
specified primary analysis at 24 weeks has taken these
small numbers into account, and statistical significance
was achieved only because of the large effect sizes
observed. The effect sizes of−5.4 ADAS-cog units and
3.8 MMSE units are clinically meaningful at 24 weeks.
Another potential limitation is the lack of urinary
discoloration in the placebo arm at 24 weeks. How-
ever, discoloration is known not to be proportional to
MTC dose [19], and clinical procedures were imple-
mented to minimize its potential impact on efficacy
rating. It is unlikely that this consideration undermines
the validity of the efficacy signals observed, as the
228 mg/day and 152 mg/day nominal doses delivered
via 100 mg MTC capsules proved to be ineffective
despite being absorbed and producing discoloration,
hematological changes, and clinical AEs at 24 and
50 weeks. In particular, the treatment effect of the
138 mg/day dose at 50 weeks was determined relative
to an available dose of 73 mg/day in the control arm.
We have shown that a dose of 8 mg/day is sufficient
to cause adequate discoloration of excreta to ensure
blinding. Therefore the treatment effect observed at 50
weeks in the 138 mg/day group was not confounded
by absence of urinary discoloration in the control arm.
Most importantly, the molecular imaging findings pro-
vide independent biological confirmation at 24 weeks
that the 138 mg/day dose is the most effective.
The benefits seen at 24 weeks were sustained
to 50 weeks such that the overall decline in sub-
jects randomized to this dose was not significantly
different from zero (0.27 ± 0.74 ADAS-cog units
[mean ± S.E.], p = 0.714). From our meta-analysis of
previously reported studies, the decline expected in
clinical trial populations of mild or moderate AD at
12 months is 4.4 ± 1.8 (mean ± S.E.). While the effi-
cacy data at 50 weeks, being as they are exploratory
and post hoc, cannot support an inferential claim in the
same way that the 24 week data can, they are neverthe-
less informative as a basis for planning confirmatory
phase 3 trials. The primary purpose of a phase 2 trial in a
new treatment paradigm is to inform the design of con-
firmatory phase 3 trials by providing an estimate of the
expected effect size. Notwithstanding the limitations of
the 50-week data, they provide an empirical estimate
of effect size at the minimal effective dose expected in
a mild/moderate population at 12 months in a linear
mixed effects unstructured correction matrix analy-
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sis without imputatoin as approximately 90% ± 35%
(mean ± S.E.) of the expected placebo decline as a
basis for planning further studies.
The present study identified a dose of 138 mg/day
as the minimum effective dose required to prevent
decline on three clinical outcome measures and on
rCBF decline at 24 weeks. The AEs seen at the 138 mg
MT/day dose, which were predominantly mild and
restricted to the gastrointestinal system and micturi-
tion, do not preclude further clinical development.
While the results support further confirmatory stud-
ies with MT, these cannot be conducted using MTC
because of absorption and longer term tolerability
limitations. The absorption limitations at the highest
nominal dose of 228 mg/day limited delivery to an
available dose of 109 mg/day. Therefore, the present
study did not permit determination of whether greater
efficacy than seen at the 138 mg/day dose is achiev-
able at a higher available dose without significant loss
of tolerability or safety. Global phase 3 studies in
mild and moderate AD are now fully recruited and
will report in 2016. They investigate MT doses in the
range 150–250 mg/day using a stable reduced form
(LMTX®) that directly delivers LMT without need for
active conversion from MT+, is better tolerated, and
does not suffer from the dose-dependent absorption
limitations of MTC [17].
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